A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma

Sponsor
Genentech, Inc.
Study ID
NCT00109200
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with continued Xolair treatment. Subject eligibility will be based on disease severity and asthma deterioration upon withdrawal of Xolair treatment. Subjects whose last Xolair dose was \<9 months prior to screening visit will continue with the same Xolair dosing regimen that they received in the previous Genentech or Novartis clinical study.

Key Dates

Start date
May 31, 2003
Status verified
Jun 2013
Completion
Sep 30, 2003

Study Design

Primary purpose
TREATMENT

Related Studies